[ad_1]
Mandela, P. & Ordway, G. A. The norepinephrine transporter and its regulation. J. Neurochem. 97, 310–333 (2006).
Broer, S. & Gether, U. The solute carrier 6 family of transporters. Br. J. Pharmacol. 167, 256–278 (2012).
Pertovaara, A. Noradrenergic pain modulation. Prog. Neurobiol. 80, 53–83 (2006).
Hurlemann, R. et al. Noradrenergic modulation of emotion-induced forgetting and remembering. J. Neurosci. 25, 6343–6349 (2005).
Pignatelli, M. & Bonci, A. Role of dopamine neurons in reward and aversion: a synaptic plasticity perspective. Neuron 86, 1145–1157 (2015).
Navratna, V. & Gouaux, E. Insights into the mechanism and pharmacology of neurotransmitter sodium symporters. Curr. Opin. Struct. Biol. 54, 161–170 (2019).
Pramod, A. B., Foster, J., Carvelli, L. & Henry, L. K. SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol. Aspects Med. 34, 197–219 (2013).
Rudnick, G., Kramer, R., Blakely, R. D., Murphy, D. L. & Verrey, F. The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction. Pflugers Arch. 466, 25–42 (2014).
Stahl, S. M., Lee-Zimmerman, C., Cartwright, S. & Morrissette, D. A. Serotonergic drugs for depression and beyond. Curr. Drug Targets 14, 578–585 (2013).
Lambert, O. & Bourin, M. SNRIs: mechanism of action and clinical features. Expert Rev. Neurother. 2, 849–858 (2002).
Hajos, M., Fleishaker, J. C., Filipiak-Reisner, J. K., Brown, M. T. & Wong, E. H. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 10, 23–44 (2004).
Shao, L., Li, W., Xie, Q. & Yin, H. Triple reuptake inhibitors: a patent review (2006–2012). Expert Opin. Ther. Pat. 24, 131–154 (2014).
Tu, G. et al. Understanding the polypharmacological profiles of triple reuptake inhibitors by molecular simulation. ACS Chem. Neurosci. 12, 2013–2026 (2021).
Jayanthi, L. D., Samuvel, D. J. & Ramamoorthy, S. Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. Evidence for localization in lipid rafts and lipid raft-mediated internalization. J. Biol. Chem. 279, 19315–19326 (2004).
Magnani, F., Tate, C. G., Wynne, S., Williams, C. & Haase, J. Partitioning of the serotonin transporter into lipid microdomains modulates transport of serotonin. J. Biol. Chem. 279, 38770–38778 (2004).
Luethi, D. et al. Phosphatidylinositol 4,5-bisphosphate (PIP2) facilitates norepinephrine transporter dimerization and modulates substrate efflux. Commun. Biol. 5, 1259 (2022).
Hamilton, P. J. et al. PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nat. Chem. Biol. 10, 582–589 (2014).
Buchmayer, F. et al. Amphetamine actions at the serotonin transporter rely on the availability of phosphatidylinositol-4,5-bisphosphate. Proc. Natl Acad. Sci. USA 110, 11642–11647 (2013).
Anderluh, A. et al. Direct PIP2 binding mediates stable oligomer formation of the serotonin transporter. Nat. Commun. 8, 14089 (2017).
Seidel, S. et al. Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol. Pharmacol. 67, 140–151 (2005).
Coleman, J. A., Green, E. M. & Gouaux, E. X-ray structures and mechanism of the human serotonin transporter. Nature 532, 334–339 (2016).
Coleman, J. A. & Gouaux, E. Structural basis for recognition of diverse antidepressants by the human serotonin transporter. Nat. Struct. Mol. Biol. 25, 170–175 (2018).
Coleman, J. A. et al. Serotonin transporter–ibogaine complexes illuminate mechanisms of inhibition and transport. Nature 569, 141–145 (2019).
Yang, D. & Gouaux, E. Illumination of serotonin transporter mechanism and role of the allosteric site. Sci. Adv. 7, eabl3857 (2021).
Penmatsa, A., Wang, K. H. & Gouaux, E. X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503, 85–90 (2013).
Wang, K. H., Penmatsa, A. & Gouaux, E. Neurotransmitter and psychostimulant recognition by the dopamine transporter. Nature 521, 322–327 (2015).
Penmatsa, A., Wang, K. H. & Gouaux, E. X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat. Struct. Mol. Biol. 22, 506–508 (2015).
Pidathala, S., Mallela, A. K., Joseph, D. & Penmatsa, A. Structural basis of norepinephrine recognition and transport inhibition in neurotransmitter transporters. Nat. Commun. 12, 2199 (2021).
Holton, K. L., Loder, M. K. & Melikian, H. E. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat. Neurosci. 8, 881–888 (2005).
Cheng, M. H. & Bahar, I. Monoamine transporters: structure, intrinsic dynamics and allosteric regulation. Nat. Struct. Mol. Biol. 26, 545–556 (2019).
Wang, H. et al. Structural basis for action by diverse antidepressants on biogenic amine transporters. Nature 503, 141–145 (2013).
Tatsumi, M., Groshan, K., Blakely, R. D. & Richelson, E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340, 249–258 (1997).
Sorensen, L. et al. Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket. J. Biol. Chem. 287, 43694–43707 (2012).
Mason, J. N. et al. Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J. Pharmacol. Exp. Ther. 323, 720–729 (2007).
Andersen, J. et al. Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proc. Natl Acad. Sci. USA 108, 12137–12142 (2011).
Bymaster, F. P. et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27, 699–711 (2002).
Gregori-Puigjane, E. et al. Identifying mechanism-of-action targets for drugs and probes. Proc. Natl Acad. Sci. USA 109, 11178–11183 (2012).
Rothman, R. B. & Baumann, M. H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol. 479, 23–40 (2003).
Hill, E. R., Huang, X., Zhan, C. G., Ivy Carroll, F. & Gu, H. H. Interaction of tyrosine 151 in norepinephrine transporter with the 2β group of cocaine analog RTI-113. Neuropharmacology 61, 112–120 (2011).
Jayaraman, K. et al. Dopamine transporter oligomerization involves the scaffold domain, but spares the bundle domain. PLoS Comput. Biol. 14, e1006229 (2018).
Cheng, M. H., Garcia-Olivares, J., Wasserman, S., DiPietro, J. & Bahar, I. Allosteric modulation of human dopamine transporter activity under conditions promoting its dimerization. J. Biol. Chem. 292, 12471–12482 (2017).
Periole, X., Zeppelin, T. & Schiott, B. Dimer Interface of the human serotonin transporter and effect of the membrane composition. Sci. Rep. 8, 5080 (2018).
Pidathala, S. et al. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2. Nature 623, 1086–1092 (2023).
Singh, S. K., Piscitelli, C. L., Yamashita, A. & Gouaux, E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 322, 1655–1661 (2008).
Liu, S. et al. Cryo-EM structures of the human cation-chloride cotransporter KCC1. Science 366, 505–508 (2019).
Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
Zeppelin, T., Ladefoged, L. K., Sinning, S., Periole, X. & Schiott, B. A direct interaction of cholesterol with the dopamine transporter prevents its out-to-inward transition. PLoS Comput. Biol. 14, e1005907 (2018).
Loland, C. J., Norregaard, L., Litman, T. & Gether, U. Generation of an activating Zn2+ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc. Natl Acad. Sci. USA 99, 1683–1688 (2002).
Schmitt, K. C. et al. Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. J. Neurochem. 107, 928–940 (2008).
Goehring, A. et al. Screening and large-scale expression of membrane proteins in mammalian cells for structural studies. Nat. Protoc. 9, 2574–2585 (2014).
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531–544 (2018).
[ad_2]
Source link